Steve Elms bought $35k of MRKR
director at Marker Therapeutics, Inc.. 11,085 shares at an average of $3.20, traded Dec 23, 2024, filed Dec 26, 2024.
Score components
- +15RoleDirector
- +6Trade size$35k at market
- 0Relative to holdingsHoldings up 3.5%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-24-131704, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 23, 2024 | POpen-market purchase Common Stockindirect: See Footnote | +11,085 | $3.20 | $35k | 325,370 | Dec 26, 2024 |
Related signals
Other insiders at Marker Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Marker Therapeutics, Inc. | New Enterprise Associates 16, L.P. owner | $1.8M 554,250 shares | +52% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.